WallStreetZenWallStreetZen

NASDAQ: AGMB
Agomab Therapeutics Nv Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AGMB

Based on 3 analysts offering 12 month price targets for Agomab Therapeutics Nv

Min Forecast
$28.00+153.39%
Avg Forecast
$32.00+189.59%
Max Forecast
$36.00+225.79%

Should I buy or sell AGMB stock?

Based on 3 analysts offering ratings for Agomab Therapeutics Nv.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AGMB's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates AGMB as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their AGMB stock forecasts and price targets.

AGMB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-03
lockedlocked$00.00+00.00%2026-03-03
lockedlocked$00.00+00.00%2026-03-03

1 of 1

Forecast return on equity

Is AGMB forecast to generate an efficient return?

Company
N/A
Industry
65.32%
Market
171.88%

Forecast return on assets

Is AGMB forecast to generate an efficient return on assets?

Company
N/A
Industry
30.14%

AGMB earnings per share forecast

What is AGMB's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.63
Avg 2 year Forecast
-$1.72

AGMB revenue forecast

What is AGMB's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$1.4M
Avg 2 year Forecast
$1.7M
Avg 3 year Forecast
$0.0

AGMB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AGMB$11.05$32.00+189.59%Strong Buy
TECX$28.54$67.50+136.51%Strong Buy
ENGN$7.99$21.08+163.87%Buy
OCGN$1.66$9.75+487.35%Strong Buy
KYTX$9.06$26.00+186.98%Strong Buy
View Top Biotech Stocks

Agomab Therapeutics Nv Stock Forecast FAQ

Is Agomab Therapeutics Nv Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: AGMB) stock is to Strong Buy AGMB stock.

Out of 3 analysts, 2 (66.67%) are recommending AGMB as a Strong Buy, 1 (33.33%) are recommending AGMB as a Buy, 0 (0%) are recommending AGMB as a Hold, 0 (0%) are recommending AGMB as a Sell, and 0 (0%) are recommending AGMB as a Strong Sell.

If you're new to stock investing, here's how to buy Agomab Therapeutics Nv stock.

What is AGMB's earnings growth forecast for 2026-2027?

(NASDAQ: AGMB) Agomab Therapeutics Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.63%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.53%.

Agomab Therapeutics Nv's earnings in 2026 is -$72,729,069.On average, 4 Wall Street analysts forecast AGMB's earnings for 2026 to be -$79,538,423, with the lowest AGMB earnings forecast at -$90,270,262, and the highest AGMB earnings forecast at -$67,037,440.

In 2027, AGMB is forecast to generate -$84,012,460 in earnings, with the lowest earnings forecast at -$100,300,291 and the highest earnings forecast at -$65,502,231.

What is AGMB's revenue growth forecast for 2026-2028?

(NASDAQ: AGMB) Agomab Therapeutics Nv's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.3%.

Agomab Therapeutics Nv's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast AGMB's revenue for 2026 to be $69,596,120, with the lowest AGMB revenue forecast at $0, and the highest AGMB revenue forecast at $143,286,130. On average, 4 Wall Street analysts forecast AGMB's revenue for 2027 to be $82,023,999, with the lowest AGMB revenue forecast at $0, and the highest AGMB revenue forecast at $168,872,939.

In 2028, AGMB is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is AGMB's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: AGMB) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 30.14%.

What is AGMB's Price Target?

According to 3 Wall Street analysts that have issued a 1 year AGMB price target, the average AGMB price target is $32.00, with the highest AGMB stock price forecast at $36.00 and the lowest AGMB stock price forecast at $28.00.

On average, Wall Street analysts predict that Agomab Therapeutics Nv's share price could reach $32.00 by Mar 3, 2027. The average Agomab Therapeutics Nv stock price prediction forecasts a potential upside of 189.59% from the current AGMB share price of $11.05.

What is AGMB's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: AGMB) Agomab Therapeutics Nv's current Earnings Per Share (EPS) is -$166.54. On average, analysts forecast that AGMB's EPS will be -$1.63 for 2026, with the lowest EPS forecast at -$1.85, and the highest EPS forecast at -$1.38. In 2027, AGMB's EPS is forecast to hit -$1.72 (min: -$2.06, max: -$1.34).

What is AGMB's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: AGMB) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.